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in three Romanian cities participated. A total of 140 patients were included: 60 
(42.8%) with hip, 68 (48.6%) with vertebral and 12 (8.6%) with wrist osteoporotic 
fractures. The mean [95% CI] total cost of osteoporotic fracture management was 
€ 1,155 [€ 1,044 - € 1,304] per patient. Medications (mean [95% CI], € 544 [€ 477 - € 624]) 
and hospital care (€ 447 [€ 393 - € 512]) were the major cost drivers, accounting for 
47.1% and 42.8% of the average total cost respectively. Hip fractures were more 
costly than vertebral and wrist fractures (mean [95% CI]: € 1,384 [€ 1,186 - € 1,643]; 
€ 991 [€ 852 - € 1,172]; and € 934 [€ 659 - € 1,177], respectively). ConClusions: This 
study provides the first estimates of the direct cost of osteoporotic fractures in the 
Romanian health care system. The results suggest that osteoporotic fractures pose 
a significant burden on both drug and hospital budgets. Effective treatment strategy 
to avoid such fractures may reduce this burden.
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objeCtives: To identify factors associated with the cost of RA care and calculated 
risk-adjusted costs associated with RA in Turkey. The relationships between costs 
of RA treatment and disease activity was also examined. Methods: This cross-
sectional study was performed in 10 tertiary rheumatology centers. Eligible patients 
were ≥ 18 years of age diagnosed as having RA for at least 12 months according to the 
American College of Rheumatology (ACR) 1987 criteria. Overall costs were catego-
rized as inpatient, outpatient and pharmacy costs. Generalized linear models were 
used to calculate risk-adjusted direct costs. Results: A total of 698 patients were 
studied. Patients’ visual analog scale (VAS), patient’s global disease activity (GDA) 
and routine assessment of patient index data 3 (RAPID-3) scores were on average 
44.15, 5.19 and 5.10 respectively. Most patients were prescribed immunosuppres-
sive medications and glucorticoids (87.8% and 61.2%, respectively). After adjusting 
all variables, total annual medical cost was € 2,671. The most significant portion of 
overall expenditures was due to pharmaceutical costs € 1,987, while outpatient costs 
were € 303, inpatient costs were € 360 and co-payments were € 21. 14% of patients 
experienced work loss due to RA. On average, annual costs due to workday loss were 
€ 480. 5.4% of patients also had other RA-related consultations, which were not cov-
ered by insurance, bringing the average annual burden to € 1,600 for these patients. 
6.5% of RA patients had additional costs related to their condition such as the 
need for a new car, apartment or special equipment, spending an additional € 1,640 
in 1 year. 13.7% of patients required caregivers. The average annual out-of-pocket 
amount paid to caregivers was € 624. ConClusions: The annual medical cost of 
RA in Turkey, although significantly lower compared to European estimates, causes 
considerable economic burden. Drug costs constitute the major part of annual cost 
for RA followed by indirect costs.
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objeCtives: To perform the cost of rheumatoid arthritis analysis based on inquiry 
study with patients. Methods: It is a micro costing study which was conducted 
between August and December 2012. The information was gathered with the sup-
port of the Association of patients with rheumatoid arthritis. The questionnaire 
was made and distributed to patients waiting in front the physicians’ offices. 
Clarification in case of missing data was made by phone. The questions aimed 
to gather basic information about the characteristics of the patients, their phar-
macotherapy, frequency of physicians’ visits, hospitalizations, and their health 
status self- evaluation. The direct health costs were calculated based on patients’ 
answers and insurance fund tariff. Results: A total of 119 patients participated in 
the study, and nineteen were excluded due to insufficient information. Twenty-two 
patients were male and 78 were female aged 54.78 years on average. Almost half of 
the patients (42 patients) were employed. Thirty-four of patients had duration of 
the RA less than 5 years, 19 had duration between 5-7 years, another 14 patients 
had duration of between 7-10 years and 33 patients had duration more than 10 
years. The total cost for the treatment of the patients for one month was 82 523 
BGN (per patient, per month on average 825 BGN). To one quarter of the patients 
a biological treatment was prescribed with a total cost of 74 026 BGN per year. 
Ninety-two of the patients answered that they are strictly taking their medicines. 
Our study shows that most of the patients doesn’t knows what medicines they are 
taking or even doesn’t knows their dossing regime. ConClusions: The percent-
age of the patients that are not following the doctor’s prescription is very high 
and their reliability as a source of cost studies is not sufficient that impose the 
need of patient education.
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objeCtives: To measure productivity loss of RA patients in Poland compared 
to results of selected studies. Methods: In this study consecutive patients in 
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objeCtives: The use of navigation and intraoperative imaging permits to perform 
a large number of procedures more accurately and safely. The aim of this study was 
to estimate the cost savings achieved by an integrated operating room with full 
rotation 3-D intraoperative imaging and navigation (NT) compared with a stand-
ard operating room in three types of surgery: balloon kyphoplasty, lumbar fusion, 
and fusion cervical. Methods: We developed a cost analysis through a published 
literature review of full rotation 3-D intraoperative imaging and navigation stud-
ies, taking into account a hospital perspective. We identified the studies with data 
related to hospital resource savings when compared with a standard operating 
room (imaging test outside the operating room). Subsequently, potential savings 
per patient were estimated for each surgery and were updated to euros 2013. Cost 
data were taken from e-Salud database and Spanish regional tariffs. Results: The 
use of full rotation 3-D intraoperative imaging and NT versus a standard operating 
room increases surgical process efficiency due to: avoid post surgery computer 
tomographies to confirm the success of the procedure, increase the accuracy of sur-
gical interventions, avoid complications and reduce the need for re-interventions, 
reduce the operating room time, faster patient recovery and reduce hospital length 
of stay. Potential savings by type of surgery were € 615, € 3,242, and € 4,458 for balloon 
kyphoplasty, posterior cervical fusion, lumbar fusion, respectively. ConClusions: 
The use of full rotation 3-D intraoperative imaging and NT leads to improved clinical 
outcomes and increased hospital efficiency in surgeries carried out with it. A 3-D 
intraoperative imaging system is a cost-saving strategy for balloon kyphoplasty, 
lumbar fusion, and cervical fusion surgeries from a hospital perspective.
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objeCtives: To estimate the health care utilization and expenditures for osteo-
porosis patients treated with oral bisphosphonate in Tianjin, China and examine 
factors associated with health care expenditures. Methods: Data were obtained 
from Tianjin Urban Employee Basic Medical Insurance database (2008-2010) with 
30% random sample of enrollees. The index date was the first pharmacy claim 
date of oral bisphosphonate in 2009. Patients of 40 years of age or older, continu-
ously enrolled for 12 months prior to and following the index date, were included if 
osteoporosis was diagnosed and oral bisphosphonate (alendronate and etidronate) 
was claimed accordingly. All-cause cost, osteoporosis-related cost, drug cost, and 
related health care utilization were estimated at 2009 dollars. Logistic regression 
analysis was applied to identify factors associated with expenditures. Results: 
Of 853 patients identified, 64.6% were for women. The mean age was 64.6 (±10.4) 
years. Of $2039.2 (±2782.6) all-cause cost per person per year, out-of-pocket cost 
accounted for 2.1%; drug cost accounted for 61.1%; osteoporosis-related cost 
accounted for 37.9%. Of $1026.5 (±1108.8) all-cause outpatient cost per person per 
year, drug cost accounted for 82.3%; osteoporosis-related cost accounted for 14.6%. 
Of $1012.7 (±2586.2) all-cause inpatient cost per person per year, drug cost accounted 
for 39.6%; osteoporosis-related cost accounted for 61.5%. An average of 7.0 (±3.7) 
outpatient visits and 0.4 (±0.8) hospitalization admissions were found. Regression 
results demonstrated that patients with diabetes mellitus and nephropathy had 
higher all-cause cost; female patients and patients with pre-fracture had higher 
osteoporosis-related cost. ConClusions: The economic burden of osteoporosis is 
high for osteoporosis patients and is expected to increase considering the increment 
of life expectancy and the increasing number of elderly population. Greater empha-
sis and policy guidance should be given to the impact of osteoporosis prevention 
and treatment in elderly population.
PMS32
the coSt of oSteoPoRotic fRactuReS in the RoManian 
PoStMenoPauSal woMen PoPulation
Mihalache M.1, Berghea F.2, Botez I.3, Dumitru C.4, Grigorie D.5, Ionescu R.6, Lupescu O.7, 
Opris D.6, Poiana C.5, Stanciu S.8, Psachoulia E.9, Intorcia M.9
1Amgen Romania SRL, Bucharest, Romania, 2Carol Davila University Of Medicine and Pharmacy, 
Bucharest, Romania, 3Spitalul Clinic de Recuperare Iasi, Iasi, Romania, 4Spitalul Municipal 
Ploiesti, Ploiesti, Romania, 5Institutul National de Endocrinologie “C.I. Parhon”, Bucharest, 
Romania, 6Spitalul Sf. Maria, Bucharest, Romania, 7Spitalul Clinic de Urgenta Floreasca, 
Bucharest, Romania, 8Spitalul Judetean de Urgenta Ploiesti, Ploiesti, Romania, 9Amgen (Europe) 
GmbH, Zug, Switzerland
objeCtives: Little data are available regarding the economic burden of osteoporosis 
on the Romanian (public payer) health care system. This retrospective chart review 
estimated the direct costs of osteoporotic fractures in postmenopausal women in 
Romania. Methods: Women aged > 65 years diagnosed with osteoporosis, who 
sustained an osteoporotic hip, wrist or vertebral fracture between December 1, 
2007 and November 1, 2011 (and 1-5 years prior to study enrolment), admitted as 
inpatients to a sample of Romanian general and specialist hospitals were eligible; 
patients with multiple fractures or fractures resulting from co-morbidities were 
excluded. The duration of post-fracture follow-up was one year. The cost perspective 
included direct costs incurred by the Romanian national health insurance agency 
and the patients’ own budgets. Health care utilization was recorded from hospital 
and primary care resources, and then multiplied with national tariffs to obtain 
total costs. Bootstrapping was conducted to generate bias corrected and accelerated 
confidence intervals. Results: Five general hospitals and two specialist hospitals 
